Endo International Plc has announced its plans to acquire Par Pharmaceutical Holdings Inc. from private-equity firm TPG, in a deal worth $8.05 billion, as the Irish-based company looks to become one of the top five firms in the generic drugs business.
Why Endo looking for this acquisition?
The consolidation is expected to create a very strong generic drugs platform for Endo, giving rise to a generics business that would rank among the top five in the industry, in terms of US sales.
Par’s generic drugs portfolio consists of approximately 100 products which are sold in various delivery forms, ranging from oral solids to oral suspensions as well as injectables; all these drugs have been raking in high profits for the privately held firm.
Moreover, Par Pharma’s experimental drugs pipeline consists of various late-stage candidates that are already up for regulatory approvals, further adding to the high growth prospects for Endo in the long run. Par’s current research and development pipeline comprises of around 200 Abbreviated New Drug Applications (ANDAs), out of which almost 115 have already been submitted to the FDA for approval.
About Endo International PLC.
Endo International plc is a global specialty healthcare company focused on improving the lives of patients’ while creating value. Endo develops, manufactures, markets, and distributes quality branded pharmaceutical, generic pharmaceutical, over the counter medications and medical device products through its operating companies.
Through operating companies – Endo Pharmaceuticals, Qualitest, AMS, Paladin Labs and SOMAR – Endo is dedicated to providing products that meet the unmet needs of patients.
|Endo Pharmaceuticals||Branded Pharmaceuticals|
|AMS||Devices for Pelvic Health Solutions|
|Qualitest||Generic and Over-the-Counter Drugs|
|Paladin Labs||Innovative Pharmaceutical Products for the Canadian Market|
|SOMAR||High-Quality Pharmaceutical Products for Key Market Segments in Mexico|
Areas of Focus
Endo has a long-standing history and success in developing and delivering quality products to our customers. Our current portfolio is associated with a broad set of therapeutic areas including:
- Allergy Immunotherapy
- Central Precocious Puberty (CPP)
- Infectious Disease
- Pelvic Health
- Men’s Health
- Women’s Health